Research programme: stem cell therapy - Kangstem Biotech

Drug Profile

Research programme: stem cell therapy - Kangstem Biotech

Alternative Names: Induced Neural Stem Cells - Kangstem Biotech; iNSC; Second generation Furestem® - Kangstem Biotech

Latest Information Update: 08 Nov 2016

Price : $50

At a glance

  • Originator Kangstem Biotech
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atherosclerosis; Osteoarthritis
  • Research Neurological disorders

Most Recent Events

  • 26 Oct 2016 Early research in Neurological disorders in South Korea (Parenteral) before October 2016 (Kangstem Biotech pipeline, October 2016)
  • 26 Oct 2016 Preclinical trials in Atherosclerosis in South Korea (Parenteral) before October 2016 (Kangstem Biotech pipeline, October 2016)
  • 26 Oct 2016 Preclinical trials in Osteoarthritis in South Korea (Parenteral) before October 2016 (Kangstem Biotech pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top